A leading breast cancer specialist examines the growing role of CDK4/6 inhibitors in the adjuvant treatment of HR+/HER2- early breast cancer, citing the monarchE and NATALEE trials, and explores patient and disease-related factors that guide the decision to incorporate CDK4/6 inhibitors in this context.
Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin
November 11th 2025Cefdinir is linked to nearly double the outpatient uncomplicated UTI treatment failure of cephalexin, with higher recurrence and increased resistance to other cephalosporins.
Read More